Results 131 to 140 of about 1,428 (167)
SGLT2 Inhibitors and the Risk of Infections in Type 2 Diabetes: Systematic Review and Meta-Analyses of Real-World Evidence. [PDF]
J Diabetes ResAlfonso Arvez MJ +4 more
europepmc +1 more source
Could Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Play a Role in Gout Treatment? [PDF]
PharmaceuticsKaufmann D, Schlesinger N.
europepmc +1 more source
Pharmacological profile of tofogliflozin, a novel SGLT2 inhibitor, in preclinical studies
, 2014 openaire +1 more source
Pharmacological profile of tofogliflozin, a novel SGLT2 inhibitor, in preclinical studies
Pharmacological profile of tofogliflozin, a novel SGLT2 inhibitor, in preclinical studiesopenaire +1 more source
A Scalable Synthesis of Tofogliflozin Hydrate
Organic Process Research and Development, 2016 A newly process for the synthesis of tofogliflozin hydrate, a sodium-glucose cotransporter type 2 (SGLT2) inhibitor, was described. Three improvements were achieved, including the development of a regioselective Friedel–Crafts reaction, a high-yield reduction, and a mild metal–halogen exchange. These improvements ultimately resulted in the isolation of
Xiu-Dong Yang +7 more
exaly +3 more sources
Drug Research, 2017 Abstract Tofogliflozin is a selective oral inhibitor of sodium-glucose co-transporter 2 for treatment of type 2 diabetes mellitus. The pharmacokinetics, pharmacodynamics, and safety of tofogliflozin were investigated in healthy male subjects. Three studies were conducted: single-ascending dose study (10–640 mg) in 56 Japanese and 24 Caucasian subjects;
Yuji Kumagai +2 more
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Impact of tofogliflozin on hepatic outcomes: a systematic review
European Journal of Clinical Pharmacology, 2023Studies have demonstrated a high prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients. The aim was to review the effect of tofogliflozin on hepatic outcomes in T2DM patients.A literature search in PubMed, Science Direct and Cochrane Central Register of Controlled Trials was conducted for randomised ...
Nidhi B. Agarwal, Rizwana Parveen
exaly +3 more sources
Tofogliflozin Salt Cocrystals with Sodium Acetate and Potassium Acetate
Chemical and Pharmaceutical Bulletin, 2018 We investigated the salt cocrystals formed by tofogliflozin with sodium acetate and potassium acetate by determining the crystal structures of the salt cocrystals and characterizing the solid states. The salt cocrystal screening using the slurry method and the liquid-assisted grinding method resulted in the formation of tofogliflozin-sodium acetate 1 :
Yuichi Tozuka +2 more
exaly +4 more sources
Organic Process Research and Development, 2019 The synthesis of tofogliflozin (1), a sodium glucose cotransporter 2 (SGLT2) inhibitor, was achieved through the key steps of intramolecular [4 + 2] cycloaddition of dienone-yne intermediate, aerobic aromatization, and anomeric equilibration, thus ...
Masatoshi Murakata
exaly +2 more sources
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes
Expert Opinion on Pharmacotherapy, 2019Accumulating data from recent studies has altered the gold standard of care for diabetes treatment. In patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or those at high risk for CVD, subsequently to lifestyle changes and metformin therapy, the administration of an SGLT-2 inhibitor with established benefits for ...
Itamar Raz
exaly +3 more sources